Meet Bench­ling, the lat­est uni­corn seek­ing to rev­o­lu­tion­ize the way sci­en­tists do work with the help of the cloud

There’s an­oth­er uni­corn in biotech land, as Bench­ling and its lead­ing R&D cloud plat­form pull in a $200 mil­lion Se­ries E to help sci­en­tists ac­cel­er­ate drug de­vel­op­ment. In do­ing so, the com­pa­ny hit a lofty $4 bil­lion val­u­a­tion — near­ly five times what it was worth around this time last year, ac­cord­ing to Forbes.

De­spite the fact that drug de­vel­op­ment is be­com­ing sig­nif­i­cant­ly more com­plex, the in­dus­try con­tin­ues to run on pa­per, emails and spread­sheets, co-founder and CEO Sajith Wick­ra­masekara said in a video on Bench­ling’s web­site. The for­mer MIT stu­dent sought to change that by cre­at­ing soft­ware that al­lows sci­en­tists to bet­ter track, mod­el and fore­cast their work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER